Gap 27
Gap 27 性质
| 密度 | 1.40±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | −20°C |
| 溶解度 | 在1%乙酸中溶解度为1mg/ml |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.41±0.10(Predicted) |
| 颜色 | 白色至米白色 |
| 生物来源 | human |
| 水溶解性 | Soluble to 1 mg/ml in water |
| 序列 | H-Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile-OH |
| InChIKey | SXRAPDIXXYFGJG-MDAHIHQXSA-N |
Gap 27 用途与合成方法
Gap 27 causes a remarked decrease in the number of both TRAP-positive mononuclear and multinucleated rat osteoclasts cultured on bovine bone slices. The activity of the remaining osteoclasts is found to be diminished by measuring the percentage of osteoclasts with actin rings of all TRAP-positive cells. In addition, the resorbed area in the treated cultures is greatly diminished. Incubation of the carotid artery with the gap junction inhibitor Gap 27 (500 μM) essentially abolishes the hyperpolarization to acetylcholine but it is without effect on that to levcromakalim. In the guinea-pig isolated internal carotid artery, Gap 27 inhibits acetylcholine-induced, endothelium-dependent hyperpolarizations.
Gap 27 (300 μM) inhibits relaxation by 40% in thoracic aorta and the superior mesenteric artery. Gap 27 also attenuates the endothelium-dependent component of the relaxation induced by ATP in thoracic aorta. .
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
Gap 27 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-P0139 | 198284-64-9 | 198284-64-9 | 1mg | 400 |
| 2026-06-05 | HY-P0139 | 198284-64-9 | 198284-64-9 | 5mg | 950 |
